KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to $1.2 billion.

  • Teva Pharmaceutical Industries' Other Accumulated Expenses rose 1588.24% to $1.2 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.2 billion, marking a year-over-year increase of 1588.24%. This contributed to the annual value of $1.2 billion for FY2025, which is 1588.24% up from last year.
  • As of Q4 2025, Teva Pharmaceutical Industries' Other Accumulated Expenses stood at $1.2 billion, which was up 1588.24% from $1.1 billion recorded in Q3 2025.
  • Teva Pharmaceutical Industries' Other Accumulated Expenses' 5-year high stood at $1.2 billion during Q3 2024, with a 5-year trough of $739.0 million in Q1 2021.
  • Over the past 5 years, Teva Pharmaceutical Industries' median Other Accumulated Expenses value was $986.5 million (recorded in 2023), while the average stood at $992.3 million.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first crashed by 3034.87% in 2021, then soared by 2274.98% in 2024.
  • Quarter analysis of 5 years shows Teva Pharmaceutical Industries' Other Accumulated Expenses stood at $903.0 million in 2021, then rose by 11.3% to $1.0 billion in 2022, then grew by 3.88% to $1.0 billion in 2023, then dropped by 2.3% to $1.0 billion in 2024, then grew by 15.88% to $1.2 billion in 2025.
  • Its Other Accumulated Expenses was $1.2 billion in Q4 2025, compared to $1.1 billion in Q3 2025 and $940.0 million in Q2 2025.